Alzheimer’s Field Pivots to Tau

LondonAmyloid drugs delivered only modest benefit.

Researchers at this week’s conference are shifting toward tau and ways to cross the blood-brain barrier, long the bottleneck for neurological drugs.

New tau-targeted trial results, due later this year, will show whether reversal is possible.

Sources: STAT